Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent therapeutic prospects for Machado–Joseph disease

30 Jun 2020

Abstract excerpt

PURPOSE OF REVIEW: Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3), is a fatal, dominantly inherited, neurodegenerative disease caused by expansion of a CAG repeat in the coding region of the ATXN3 gene. No disease-modifying treatment is yet available for MJD/SCA3. This review discusses recently developed therapeutic strategies that hold promise as future effective treatments for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis Research
Share to Genetic Neurodegenerative Diseases
Share to Hereditary Neurological Disorders

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32657894
DOI: 10.1097/wco.0000000000000832

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent therapeutic prospects for Machado–Joseph diseasePMID 32657894Read ↗

Machado–Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapySemantic proximity Read ↗

Machado Joseph disease: clinical and genetic aspects, and current treatmentSemantic proximity Read ↗

Pharmacological Therapies for Machado-Joseph Disease.Semantic proximity Read ↗

Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to TherapeuticsSemantic proximity Read ↗

Machado-Joseph Disease: from first descriptions to new perspectives.Semantic proximity Read ↗

Toward understanding Machado-Joseph disease.Semantic proximity Read ↗

Toward RNAi Therapy for the Polyglutamine Disease Machado–Joseph DiseaseSemantic proximity Read ↗

Caring for Machado-Joseph disease: current understanding and how to help patients.Semantic proximity Read ↗

Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado–Joseph Disease through Integration of Pathological Biomarkers and Therapeutic StrategiesSemantic proximity Read ↗

Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense TherapiesSemantic proximity Read ↗

Dominantly inherited ataxias: lessons learned from Machado-Joseph disease/spinocerebellar ataxia type 3.Semantic proximity Read ↗

Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.